Pliant Therapeutics, Inc.

General ticker "PLRX" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $644.1M (TTM average)

Pliant Therapeutics, Inc. follows the US Stock Market performance with the rate: 13.0%.

Estimated limits based on current volatility of 5.0%: low 1.49$, high 1.65$

Factors to consider:

  • Earnings expected soon, date: 2025-05-05 bmo
  • Current price 75.9% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [7.00$, 17.99$]
  • 2025-12-31 to 2026-12-31 estimated range: [6.52$, 16.89$]

Financial Metrics affecting the PLRX estimates:

  • Negative: Non-GAAP EPS, $ of -3.47 <= 0.04
  • Negative: Operating cash flow per share per price, % of -15.47 <= 1.79
  • Negative: negative Net income
  • Negative: negative Operating income
  • Positive: Interest expense per share, $ of 0.05 <= 0.10
  • Negative: Industry operating cash flow per share per price (median), % of -8.00 <= 2.82
  • Negative: negative Industry operating income (median)
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term PLRX quotes

2025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-021.11.21.31.41.51.61.7
Price $

Long-term PLRX plot with estimates

05101520253035Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−1−0.50
PLRXS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $9.69MM $1.58MM $0.00MM
Operating Expenses $136.88MM $185.72MM $228.37MM
Operating Income $-127.20MM $-184.15MM $-228.37MM
Non-Operating Income $3.88MM $22.81MM $18.06MM
Interest Expense $0.79MM $1.27MM $3.02MM
R&D Expense $96.94MM $127.80MM $169.31MM
Income(Loss) $-123.32MM $-161.34MM $-210.30MM
Profit(Loss)* $-121.50MM $-161.34MM $-210.30MM
Stockholders Equity $313.34MM $473.58MM $304.08MM
Inventory $0.00MM $0.00MM $0.00MM
Assets $350.61MM $512.15MM $396.95MM
Operating Cash Flow $-94.63MM $-116.36MM $-155.50MM
Capital expenditure $1.76MM $0.92MM $3.85MM
Investing Cash Flow $-150.20MM $-127.01MM $140.34MM
Financing Cash Flow $226.85MM $274.40MM $23.12MM
Earnings Per Share** $-2.89 $-2.75 $-3.47

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.